New Merck & Co opens for business
November 5, 2009Sales and Marketing MA, Merck, restructure
The new corporate entity formed by the Merck & Co/Schering-Plough merger has at last opened its doors for business.The Schering-Plough …
Digital Pharma: Pfizer’s multi-media dead rat
November 4, 2009Medical Communications Pfizer, counterfeits, digi, get real
Pfizer has given a multi-media boost to its hard-hitting ‘dead rat’ campaign, which warns about the dangers of buying counterfeit …
Actelion UK appoints Robin Bhattacherjee General Manager
November 4, 2009Research and Development, Sales and Marketing Actelion, appointment, research and development, sales and marketing
Actelion UK has appointed Robin Bhattacherjee general manager for the UK and Ireland. He will be based at the company’s …
GlaxoSmithKline-Pfizer launch HIV joint venture
November 4, 2009Research and Development, Sales and Marketing GSK, HIV, Pfizer, ViiV
GlaxoSmithKline and Pfizer have launched a specialist HIV company with access to ten medicines developed by the two manufacturers.ViiV Healthcare, …
DSM looking for new Chinese ingredient partners
November 4, 2009Manufacturing and Production CMO, DSM
Dutch fine chemicals company DSM has said it will look for new partners in China after dissolving a joint venture …
Univar Europe appoints Michael Cooke
November 3, 2009Manufacturing and Production appointment, manufacturing and production, univar
Univar Europe has strengthened its pharma team with the appointment of Michael Cooke.Cooke, who was previously Univar’s director of safety, …
Dr John Nash, Senior Director ADME/PK, BioFocus
November 3, 2009Research and Development appointment, biofocus, research and development
BioFocus, a leading provider of gene-to-drug candidate discovery services, has appointed Dr John Nash as senior director, ADME/PK. John has …
Phase III success for GSK’s lupus drug
November 3, 2009Research and Development, Sales and Marketing Benlysta, GSK
GlaxoSmithKline’s lupus drug Benlysta has been successful in the second of two phase III trials, following earlier performance that exceeded …
Whatever happened to yesterday’s ‘magic bullets’?
November 3, 2009Research and Development Les Rose, biotech
How many of you remember when monoclonal antibodies were called `magic bullets’? Enough time has passed since the term first …
Fast times at contract research firm PPD
November 3, 2009Research and Development CRO
Pharmaceutical Product Development (PPD) has unveiled several new initiatives to re-inject some growth momentum into the business as its third-quarter …
UK lung cancer patients face ‘unacceptable postcode lottery’
November 3, 2009NHS
Lung cancer patients in the UK face an "unacceptable postcode lottery", according to the first national review of lung cancer …
GSK-Genmab blood cancer drug approved in US
November 2, 2009Research and Development, Sales and Marketing Arzerra
GlaxoSmithKline and Philadelphia-based Genmab have received accelerated US approval for their blood cancer drug Arzerra. It is to be used …
Lonza cuts staff, issues profits warning
November 2, 2009Manufacturing and Production CMO
Swiss contract manufacturer and fine chemical firm Lonza has announced it will cut around 5% of its workforce and may …
Jackie Ilacqua, head of oncology, Synovate
November 2, 2009Sales and Marketing appointment, sales and marketing, synovate
Synovate has appointed Jackie Ilacqua to the newly-created role of head of oncology.Formerly responsible for building and managing Synovate’s global …
AstraZeneca withdraws filings for lung cancer drug
November 2, 2009Research and Development, Sales and Marketing AZ, zactima
AstraZeneca has withdrawn marketing applications for its lung cancer drug Zactima in Europe and the US after evaluating updated results …
GSK returns to growth despite US sales hit
October 28, 2009Sales and Marketing GSK, generics
GlaxoSmithKline suffered a hit in the US during the third quarter of the year, with sales down 12% to £2.14 …
GSK begins phase III COPD trials
October 28, 2009Research and Development, Sales and Marketing COPD, GSK, GlaxoSmithKline, Seretide, Theravance, resp, respiratory
GlaxoSmithKline and San Francisco biopharma firm Theravance have begun a phase III trial to develop a new treatment for chronic …
Claude Bertrand joins Ipsen as Chief Scientific Officer
October 27, 2009Research and Development appointment, ipsen, research and development
Ipsen has appointed Claude Bertrand (pictured) chief scientific officer and Jacques-Pierre Moreau chief scientific advisor.Bertrand moves to the company next …
Merck KGaA’s rising revenues fail to lift bottom line
October 27, 2009Sales and Marketing Merck Serono
Revenues up, earnings down: that was the bottom line to Merck KGaA’s financial performance in the three months to the …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
